Literature DB >> 8807336

Neurofibromatosis type I gene mutation in a patient with features of LEOPARD syndrome.

R Wu1, E Legius, W Robberecht, M Dumoulin, J J Cassiman, J P Fryns.   

Abstract

Multiple lentigines (LEOPARD) syndrome has been delineated as an autosomal dominant disorder with lentigines, cardiac abnormalities, variable mental retardation, and typical craniofacial features as the most characteristic findings. LEOPARD syndrome shows a great clinical overlap with neurofibromatosis type 1 (NF1). In this report we describe a de novo missense mutation (M 1035R) in exon 18 of the NF1 gene in a young woman with a prior diagnosis of LEOPARD syndrome. We hypothesize that some patients now diagnosed with LEOPARD syndrome have in fact a mutation in the NF1 gene, whereas in other patients with LEOPARD syndrome, a different gene might be involved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807336     DOI: 10.1002/(SICI)1098-1004(1996)8:1<51::AID-HUMU7>3.0.CO;2-S

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  13 in total

1.  Multiple lentigines syndrome (LEOPARD syndrome or progressive cardiomyopathic lentiginosis).

Authors:  B D Coppin; I K Temple
Journal:  J Med Genet       Date:  1997-07       Impact factor: 6.318

2.  Reduced growth of Drosophila neurofibromatosis 1 mutants reflects a non-cell-autonomous requirement for GTPase-Activating Protein activity in larval neurons.

Authors:  James A Walker; Anna V Tchoudakova; Peter T McKenney; Suzanne Brill; Dongyun Wu; Glenn S Cowley; Iswar K Hariharan; André Bernards
Journal:  Genes Dev       Date:  2006-11-17       Impact factor: 11.361

3.  LEOPARD syndrome (PTPN11, T468M) in three boys fulfilling neurofibromatosis type 1 clinical criteria.

Authors:  Atilano Carcavilla; Isabel Pinto; Rafael Muñoz-Pacheco; Raquel Barrio; Maria Martin-Frías; Begoña Ezquieta
Journal:  Eur J Pediatr       Date:  2011-03-02       Impact factor: 3.183

4.  A clinical variant of neurofibromatosis type 1: familial spinal neurofibromatosis with a frameshift mutation in the NF1 gene.

Authors:  E Ars; H Kruyer; A Gaona; P Casquero; J Rosell; V Volpini; E Serra; C Lázaro; X Estivill
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

Review 5.  LEOPARD syndrome with recurrent PTPN11 mutation Y279C and different cutaneous manifestations: two case reports and a review of the literature.

Authors:  Ingrid Kalev; Kai Muru; Rita Teek; Riina Zordania; Tiia Reimand; Kristel Köbas; Katrin Ounap
Journal:  Eur J Pediatr       Date:  2009-09-20       Impact factor: 3.183

6.  Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype.

Authors:  D A Stevenson; D H Viskochil; A F Rope; J C Carey
Journal:  Clin Genet       Date:  2006-03       Impact factor: 4.438

7.  [Molecular genetic mutation analysis of the PTPN11 gene in the multiple lentigines (LEOPARD) syndrome].

Authors:  U G Froster; H-J Glander; W Heinritz
Journal:  Hautarzt       Date:  2003-12       Impact factor: 0.751

8.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

Authors:  Maria Cristina Digilio; Emanuela Conti; Anna Sarkozy; Rita Mingarelli; Tania Dottorini; Bruno Marino; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

9.  LEOPARD syndrome: clinical dilemmas in differential diagnosis of RASopathies.

Authors:  Claudia Santoro; Giuseppe Pacileo; Giuseppe Limongelli; Saverio Scianguetta; Teresa Giugliano; Giulio Piluso; Fulvio Della Ragione; Mario Cirillo; Giuseppe Mirone; Silverio Perrotta
Journal:  BMC Med Genet       Date:  2014-04-26       Impact factor: 2.103

10.  Pathogenesis of vestibular schwannoma in ring chromosome 22.

Authors:  Ellen Denayer; Hilde Brems; Paul de Cock; Gareth D Evans; Frank Van Calenbergh; Naomi Bowers; Raf Sciot; Maria Debiec-Rychter; Joris V Vermeesch; Jean-Pierre Fryns; Eric Legius
Journal:  BMC Med Genet       Date:  2009-09-22       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.